Central African Journal of Public Health

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Research Article |

High Late Presentation to HIV Care Among HIV-Infected Adults in Ouagadougou, Burkina Faso

Background: Because of its negative impact on HIV-related morbidity and mortality, late presentation to HIV care (LP) can be an obstacle to the HIV epidemic elimination by 2030. We assessed the prevalence and associated factors of LP in HIV-infected adults enrolled at the “Centre Medical oasis”, Ouagadougou, Burkina Faso. Methods: A cross-sectional study among HIV-infected persons aged 18 years or older, naïve for antiretroviral treatment (ART), and presented for the first time at the HIV clinic was conducted between 2015 and 2019. LP referred to HIV-infected adults presenting with CD4+ cells count < 350 /µl or WHO clinical 3 or 4 regardless of the CD4+ cell count. Late presentation to HIV care with advanced disease (LP-AD) included those with CD4+ cells count < 200 /µl or WHO clinical 3 or 4 regardless of the CD4+ cell count. Factors associated with LP were identified using logistic regressions models. Results: A total of 357 patients with median age of 34 years (interquartile range [IQR] 28-42) were included. 234 (65.6%) patients were female. Median CD4+ cell count was 305/µl (IQR 142-482). Of the 357 patients, 183 presented late to HIV care, giving a LP prevalence of 51.3% (95% confidence interval [95% CI] 45.9-56.6). Among the latter, 117 (63.9%) patients had also advanced disease. Factors associated with LP were older age (adjusted odds ratio [aOR] 2.50, 95% CI 1.33-4.71, P = 0.004), low educational level (aOR 1.99, 95% CI 1.23-3.21, P = 0.005), single status (aOR 2.07, 95% CI 1.18-3.63, P = 0.011), and family support (aOR 1.93, 95% CI 1.14-3.27, P = 0.014). Conclusion: LP and LP-AD are high among HIV-infected adults in Burkina Faso. Health authorities should urgently develop effective strategies to improve HIV testing, linkage to care, and ART initiation. They should prioritize targeting single young adults with low education.

Late Presentation, Late Presentation with Advanced Disease, HIV, Burkina Faso

Ter Tiero Elias Dah, Désiré Lucien Dahourou, Abdoulaye Hama Diallo, Issifou Yaya, Ali Sogli, et al. (2023). High Late Presentation to HIV Care Among HIV-Infected Adults in Ouagadougou, Burkina Faso. Central African Journal of Public Health, 9(5), 152-160. https://doi.org/10.11648/j.cajph.20230905.14

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61–4. doi: 10.1111/j.1468-1293.2010.00857.x.
2. Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. The Lancet Public Health 2017; 2: e35–46. doi: 10.1016/S2468-2667(16)30020-2.
3. Gabillard D, Lewden C, Ndoye I, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr 2013; 62: 555–61. doi: 10.1097/QAI.0b013e3182821821.
4. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21: 2483–91. doi: 10.1097/QAD.0b013e3282f09876.
5. Martin-Iguacel R, Reyes-Urueña J, Bruguera A, et al. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. eClinicalMedicine 2022; 52. doi: 10.1016/j.eclinm.2022.101600.
6. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306–15. doi: 10.1002/cncr.25311.
7. Fleishman JA, Yehia BR, Moore RD, et al. The economic burden of late entry into medical care for patients with HIV infection. Med Care 2010; 48: 1071–9. doi: 10.1097/MLR.0b013e3181f81c4a.
8. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS 2012; 26: 893–6. doi: 10.1097/QAD.0b013e328351f73f.
9. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793–800. doi:10.1093/cid/ciq243.
10. Fomundam HN, Tesfay AR, Mushipe SA, et al. Prevalence and predictors of late presentation for HIV care in South Africa. S Afr Med J 2017; 107: 1058–64. doi: 10.7196/SAMJ.2017.v107i12.12358.
11. Belay GM, Endalamaw A, Ayele AD. Late presentation of HIV positive adults and its predictors to HIV/AIDS care in Ethiopia: a systematic review and meta-analysis. BMC Infectious Diseases 2019; 19: 534. doi: 10.1186/s12879-019-4156-3.
12. Degno S, Atlaw D, Mekonnen A, et al. Predictors of Late Presentation for HIV/AIDS in West Arsi Zone Public Health Institutions, South Ethiopia: Unmatched Case–Control Study. HIV AIDS (Auckl) 2021; 13: 759–66. doi: 10.2147/HIV.S313139.
13. Gesesew HA, Ward P, Woldemichael K, et al. Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors. BMC Infect Dis 2018; 18: 59. doi: 10.1186/s12879-018-2971-6.
14. Lofgren SM, Tsui S, Natala N, et al. Differences in Reasons for Late Presentation to HIV Care in Uganda Among Men and Women. AIDS Behav 2023; 27: 303–13. doi: 10.1007/s10461-022-03764-9.
15. Chone JS, Abecasis AB, Varandas L. Determinants of Late HIV Presentation at Ndlavela Health Center in Mozambique. International Journal of Environmental Research and Public Health 2022; 19. doi: 10.3390/ijerph19084568.
16. Luma HN, Jua P, Donfack O-T, et al. Late presentation to HIV/AIDS care at the Douala general hospital, Cameroon: its associated factors, and consequences. BMC Infectious Diseases 2018; 18: 298. doi: 10.1186/s12879-018-3204-8.
17. Haeuser E, Serfes AL, Cork MA, et al. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. BMC Med 2022; 20: 488. doi: 10.1186/s12916-022-02639-z.
18. Institut de Recherche en Sciences de la Santé (IRSS). Etude biocomportementale sur le VIH et estimation des tailles des populations clés (HSH, TS, UD) au Burkina Faso en 2022. IBBS Key populations 2022. Rapport provisoire. Mars 2023.
19. Conseil National de Lutte contre le Sida et les IST. Cadre Stratégique National de lutte contre le VIH, le SIDA, et les infections sexuellement transmissibles (CSN-SIDA) 2021-2025. Mars 2021.
20. The Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016. BMC Infectious Diseases 2020; 20: 728. doi: 10.1186/s12879-020-05261-7.
21. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https://www.who.int/publications-detail-redirect/9789240031593 (accessed 20 Apr 2023).
22. World Health Organization. Consolidated guidelines on HIV testing services for a changing epidemic. https://www.who.int/publications-detail-redirect/WHO-CDS-HIV-19.31 (accessed 20 Apr 2023).
23. World health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. https://www.who.int/publications-detail-redirect/9789241509565 (accessed 25 Apr 2023).
24. Conseil National de Lutte contre le Sida et les IST. Normes et directives nationales de la prophylaxie pré-exposition du VIH (PrEP) par voie orale au Burkina Faso. Juin 2022.
25. Darcis G, Lambert I, Sauvage A-S, et al. Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017. Sci Rep 2018; 8: 8594. doi: 10.1038/s41598-018-26852-0.
26. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. https://www.who.int/publications-detail-redirect/9789241550062 (accessed 27 Apr 2023).
27. Prabhu S, Harwell JI, Kumarasamy N. Advanced HIV: diagnosis, treatment, and prevention. Lancet HIV 2019; 6: e540–51. doi: 10.1016/S2352-3018(19)30189-4.
28. Meya DB, Tugume L, Nabitaka V, et al. Establishing targets for advanced HIV disease: A call to action. South Afr J HIV Med 2021; 22: 1266. doi: 10.4102/sajhivmed.v22i1.1266.
29. Burke RM, Feasey N, Rangaraj A, et al. Ending AIDS deaths requires improvements in clinical care for people with advanced HIV disease who are seriously ill. The Lancet HIV 2023; 10: e482–4. doi: 10.1016/S2352-3018(23)00109-1.